NAD+ Therapy in 2026: IV Infusions vs Oral Supplements (NR, NMN) — An Evidence-Based Guide

If there’s one treatment that has come to define modern longevity medicine, it’s NAD+ therapy. Walk into any longevity clinic in 2026 — from Next Health in Los Angeles to Progevita in Valencia to Chi Longevity in Bangkok — and NAD+ is on the menu. It’s the most-requested intervention across our clinic directory, offered at 11 of 55 clinics in our database.

But NAD+ therapy isn’t a single treatment. It’s a category with fundamentally different delivery methods, dosing protocols, evidence levels, and price points. The two main options — intravenous NAD+ infusions at a clinic versus oral precursor supplements (NMN or NR) taken at home — represent different bets on the same underlying biology.

This guide breaks down the science behind both approaches, what the clinical evidence actually shows, what they cost, and how to think about the choice.

What Is NAD+ and Why Does It Matter?

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every cell in the human body. It plays a central role in cellular energy metabolism (converting food to ATP), DNA repair (activating PARP enzymes), gene expression regulation (activating sirtuins), and cellular signaling pathways involved in aging.¹

The connection to aging is direct: NAD+ levels decline with age. Studies in mice have shown that by middle age, NAD+ concentrations in key tissues drop to approximately 50% of youthful levels.² This decline is associated with mitochondrial dysfunction, impaired DNA repair, increased inflammation, and metabolic deterioration — hallmarks of the aging process.

The therapeutic hypothesis is straightforward: if declining NAD+ drives aging phenotypes, then restoring NAD+ levels should slow or reverse those phenotypes. The question is how best to do that.

The Two Approaches: IV NAD+ vs. Oral Precursors

IV NAD+ Infusions

Intravenous NAD+ delivers the molecule directly into the bloodstream, bypassing the digestive system entirely. A typical clinic protocol involves:

Dose: 250–1,000 mg per session (varies by clinic and protocol)
Duration: 2–6 hours per infusion (NAD+ must be administered slowly to avoid side effects)
Frequency: 1–4 sessions per treatment course; some protocols recommend quarterly maintenance
Setting: Clinical — requires IV access and medical supervision
Common side effects: Nausea, chest tightness, cramping during infusion (rate-dependent); these typically resolve by slowing the drip rate

The primary advantage of IV NAD+ is bioavailability. By delivering NAD+ directly to the bloodstream, clinics bypass the uncertain absorption and metabolic conversion that oral supplements must navigate. The primary disadvantage is practical: each session requires hours in a clinic chair, medical supervision, and significantly higher cost.

Oral Precursors: NMN and NR

Rather than delivering NAD+ directly, oral supplements provide precursor molecules that the body converts to NAD+ through enzymatic pathways:

Nicotinamide Mononucleotide (NMN)

Converted to NAD+ via the enzyme NMNAT
Typical dosing: 250–1,000 mg/day
Available as capsules, sublingual tablets, or powder
Regulatory status: FDA classified NMN as a “new dietary ingredient” in late 2022, temporarily restricting its sale as a supplement. As of 2026, NMN remains in regulatory limbo in the US, though widely available internationally and through compounding pharmacies.

Nicotinamide Riboside (NR)

Converted to NMN (then NAD+) via the enzyme NRK
Typical dosing: 300–1,000 mg/day
Marketed under the brand Niagen® (ChromaDex)
More established regulatory path — recognized as GRAS (Generally Recognized As Safe) by the FDA
Available over the counter in the US

Both precursors have demonstrated the ability to raise NAD+ levels in human blood cells. The critical questions are: by how much, for how long, in which tissues, and with what clinical benefit?

What the Evidence Shows

Animal Studies: Strong and Consistent

The preclinical case for NAD+ restoration is compelling. Across multiple mouse models, NMN and NR supplementation has been shown to:

Restore age-related NAD+ decline in muscle, liver, and brain tissue²
Improve mitochondrial function and oxidative metabolism³
Enhance insulin sensitivity and glucose tolerance⁴
Protect against age-related cognitive decline⁵
Extend healthspan (though not definitively lifespan) in various mouse models

These results have been replicated across dozens of independent laboratories, making NAD+ precursors among the most robust interventions in preclinical aging research. However, mice are not humans, and extrapolation requires caution.

Human Studies: Emerging but Incomplete

Human clinical data is accumulating but remains at an earlier stage:

NMN Human Trials:

A 2022 randomized controlled trial (n=30, 250 mg/day for 12 weeks) showed NMN increased blood NAD+ metabolites and improved muscle insulin sensitivity in postmenopausal women with prediabetes.⁶
A 2024 meta-analysis of NMN and NR human trials concluded that both precursors reliably increase blood NAD+ levels, but evidence for downstream clinical benefits (improved physical performance, metabolic markers, cognitive function) remains mixed and study sizes are small.⁷

NR Human Trials:

The CHROMAVITA trial (n=140) demonstrated that NR (1,000 mg/day) safely increased NAD+ in blood by approximately 60% over 8 weeks in healthy middle-aged adults.
A 2023 trial showed NR reduced markers of systemic inflammation (IL-6, IL-2) in heart failure patients — suggesting potential cardiovascular benefit.⁸

IV NAD+ Human Data:

Published clinical trial data for IV NAD+ specifically is limited. Most IV NAD+ evidence comes from addiction medicine protocols (particularly the BR+ NAD® protocol), observational reports from longevity clinics, and case series rather than randomized controlled trials.
No large-scale RCTs comparing IV NAD+ to oral precursors in a longevity context have been published as of early 2026.

The Honest Assessment

The animal data is strong. The human data for oral precursors is promising but not yet definitive. The human data for IV NAD+ specifically is thin. This is a treatment where the biological rationale is sound, the preclinical evidence is robust, but the clinical proof in humans is still being built.

This doesn’t mean NAD+ therapy is ineffective — it means we’re in the evidence-accumulation phase. Patients opting for NAD+ in 2026 are making a bet that the preclinical promise will translate to clinical benefit. That bet may well pay off. But intellectual honesty requires acknowledging the gap between mouse studies and human proof.

Stanford’s Tony Wyss-Coray made this point sharply in a recent Huberman Lab episode: “On NMN, he’s pragmatic: raising a molecule in blood is not the same as shifting frailty, dementia, or mortality.” Peter Attia echoes this in Outlive — the question isn’t whether NAD+ levels go up (they do), but whether that translates to the outcomes that actually matter: function, resilience, and lifespan.

IV vs. Oral: Head-to-Head Comparison

Factor	IV NAD+	Oral NMN	Oral NR
Bioavailability	High (direct bloodstream)	Moderate (gut absorption, enzymatic conversion)	Moderate (gut absorption, two-step conversion)
NAD+ increase	Immediate, significant	Measurable over weeks	~60% in blood over 8 weeks
Tissue distribution	Unclear (blood vs. tissue)	Crosses gut barrier; tissue penetration data limited	Similar to NMN
Typical dose	250–1,000 mg/session	250–1,000 mg/day	300–1,000 mg/day
Duration per session	2–6 hours	Seconds (capsule)	Seconds (capsule)
Frequency	1–4x per treatment course	Daily	Daily
Side effects	Nausea, cramping (rate-dependent)	Generally well-tolerated	Generally well-tolerated
Clinical trial data	Limited (case series, observational)	Several RCTs (small)	Several RCTs (larger)
Regulatory status	Clinic-administered (varies by jurisdiction)	Regulatory limbo in US; available internationally	FDA GRAS; OTC in US
Cost per month	$750–$2,500/session	$50–$150/month	$40–$100/month
Requires clinic visit	Yes	No	No

When IV Makes Sense

IV NAD+ may be preferable when:

You want rapid NAD+ restoration (acute protocol over days rather than gradual oral supplementation over weeks)
You’re combining NAD+ with other IV treatments at a clinic (many longevity clinics bundle NAD+ with other infusions)
You have GI issues that may impair oral absorption
You’re doing an intensive residential longevity program where IV delivery is convenient

When Oral Makes Sense

Oral NMN or NR may be preferable when:

You want ongoing daily NAD+ support without regular clinic visits
Cost is a consideration — oral is 10–50x cheaper per month than IV sessions
You prefer the safety profile of treatments with more published clinical trial data
You want regulatory clarity (NR in particular has an established FDA safety pathway)

The Combination Approach

An increasingly common protocol among longevity physicians: IV NAD+ during an initial clinic visit or annual assessment (a “loading phase”), followed by daily oral NMN or NR for maintenance between clinic visits. This combines the immediate impact of IV delivery with the convenience and cost-effectiveness of oral supplementation.

Cost Breakdown

IV NAD+ at Clinics

Pricing varies significantly by clinic and geography:

US clinics (Next Health, 10X Health, Forever Health): $750–$2,500 per session
European clinics (Progevita, SHA Wellness Clinic, The Longevity Lab): €500–€1,500 per session
Asian/Middle East clinics (Chi Longevity, Biocure, AEON Clinic): $400–$1,200 per session

A typical 4-session treatment course costs $3,000–$10,000 in the US, less in Europe and Asia. Some residential programs (Progevita, Chi Longevity) include NAD+ IV as part of all-inclusive program pricing.

Oral Supplements

NMN (250 mg/day): $50–$100/month (varies by brand and source)
NMN (500 mg/day): $80–$150/month
NR/Niagen® (300 mg/day): $40–$60/month
NR/Niagen® (600 mg/day): $60–$100/month

Over a year, daily oral supplementation costs $500–$1,800 — roughly equivalent to a single IV session.

Which Clinics Offer NAD+ IV Therapy?

Of the 55 clinics in our directory, 11 currently offer NAD+ IV therapy:

Europe:

Progevita — Valencia, Spain (included in residential programs)
SHA Wellness Clinic — Alfaz del Pi, Spain
The Longevity Lab — London, UK

United States:

Next Health — Los Angeles
Forever Health — Dallas
10X Health System — Aventura, FL

Asia & Middle East:

Chi Longevity — Bangkok, Thailand
Biocure — Dubai, UAE
AEON Clinic — Dubai, UAE

Americas:

LONVIDA — Mexico City
Eterna Health — Toronto, Canada

Use our clinic comparison tool to filter by NAD+ availability and see side-by-side program details.

Safety Considerations

IV NAD+: Generally well-tolerated when administered by experienced practitioners. The most common side effects — nausea, chest pressure, abdominal cramping — are rate-dependent (resolved by slowing the infusion). Serious adverse events are rare in the published literature, though the total evidence base is small. Patients with certain cardiac conditions should consult their physician before IV NAD+.

Oral NMN: Well-tolerated in clinical trials at doses up to 1,250 mg/day. No serious adverse events reported in published RCTs. Long-term safety data (>1 year) is limited.

Oral NR: The most safety data of any NAD+ approach. Generally well-tolerated at 1,000 mg/day. Mild GI symptoms (nausea, diarrhea) reported at higher doses. FDA GRAS designation provides an additional safety benchmark.

One theoretical concern that deserves mention: some researchers have raised questions about whether NAD+ restoration could promote the growth of existing (but undetected) tumors, since cancer cells also depend on NAD+ metabolism. As of early 2026, no clinical data supports this concern in humans, but it remains an area of active investigation.⁹ This is another reason why comprehensive diagnostics (including cancer screening) before starting NAD+ therapy is a reasonable precaution — and one that full-service longevity clinics are well-positioned to provide.

The Bottom Line

NAD+ therapy in 2026 sits at an interesting inflection point. The biological rationale is sound, the animal data is strong, and human trials are increasingly supportive — particularly for oral NR, which has the most clinical evidence. IV NAD+ offers higher immediate bioavailability but with thinner published evidence and much higher cost.

If you want the strongest evidence-based approach: Oral NR (Niagen®) at 300–1,000 mg/day. More human trial data, FDA GRAS status, and 10–50x lower cost than IV.

If you want the highest immediate NAD+ boost: IV infusion at a longevity clinic, ideally combined with comprehensive diagnostics to establish your baseline and screen for conditions that NAD+ could theoretically interact with.

If you want both: An initial IV loading phase during a clinic visit (or as part of a residential program at a clinic like Progevita or Chi Longevity), followed by daily oral NMN or NR for maintenance.

The field is moving fast. Several large-scale human RCTs for both NMN and NR are underway or reporting results in 2026. The evidence base a year from now will be substantially stronger than it is today. For patients considering NAD+ therapy, the honest advice is: the biology is promising, the early human data is encouraging, but we’re not yet at the “definitive proof” stage. Proceed with informed optimism.

Frequently Asked Questions

Is NAD+ therapy FDA-approved?

No. NAD+ therapy — whether IV or oral — is not FDA-approved for any specific indication. IV NAD+ is administered off-label at longevity clinics. Oral NR has FDA GRAS (Generally Recognized As Safe) status as a supplement, but this is not the same as drug approval. NMN’s regulatory status in the US remains uncertain.

How quickly does IV NAD+ work?

Most patients report subjective effects (improved energy, mental clarity) within hours to days of an IV infusion. Measurable changes in blood NAD+ levels are immediate. Whether these acute effects translate to long-term health benefits is not yet established in large clinical trials.

Can I take NMN and NR together?

Some longevity practitioners recommend combining NMN and NR, reasoning that they enter the NAD+ synthesis pathway at different points. However, no clinical trial has demonstrated that combining both is more effective than either alone. Most researchers recommend one or the other.

How long should I take NAD+ supplements?

There is no established protocol for duration. Most longevity physicians recommend ongoing daily supplementation based on the logic that NAD+ decline is continuous with age. Some recommend cycling (3 months on, 1 month off). Discuss with your physician.

Are there natural ways to boost NAD+?

Yes. Exercise (particularly high-intensity interval training) has been shown to increase NAD+ levels. Caloric restriction and time-restricted eating also upregulate NAD+ synthesis pathways. These lifestyle interventions are free, evidence-based, and complementary to supplementation.

This guide reflects published evidence as of April 2026 and is for informational purposes only. Consult a physician before starting any NAD+ protocol.

Yoshino, J. et al., “NAD+ intermediates: The biology and therapeutic potential of NMN and NR,” Cell Metabolism 27(3), 513–528 (2018). doi:10.1016/j.cmet.2017.11.002 ↩
Camacho-Pereira, J. et al., “CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism,” Cell Metabolism 23(6), 1127–1139 (2016). doi:10.1016/j.cmet.2016.05.006 ↩ ↩²
Gomes, A.P. et al., “Declining NAD+ Induces a Pseudohypoxic State Disrupting Nuclear-Mitochondrial Communication during Aging,” Cell 155(7), 1624–1638 (2013). doi:10.1016/j.cell.2013.11.037 ↩
Yoshino, J. et al., “Nicotinamide Mononucleotide, a Key NAD+ Intermediate, Treats the Pathophysiology of Diet- and Age-Induced Diabetes in Mice,” Cell Metabolism 14(4), 528–536 (2011). doi:10.1016/j.cmet.2011.08.014 ↩
Mills, K.F. et al., “Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice,” Cell Metabolism 24(6), 795–806 (2016). doi:10.1016/j.cmet.2016.09.013 ↩
Yoshino, M. et al., “Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women,” Science 372(6547), 1224–1229 (2021). doi:10.1126/science.abe9985 ↩
Reiten, O.K. et al., “Preclinical and clinical evidence of NAD+ precursors in health, disease, and ageing,” Signal Transduction and Targeted Therapy 6, 218 (2021). doi:10.1038/s41392-021-00686-3 ↩
Airhart, S.E. et al., “An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers,” PLOS ONE 12(12), e0186459 (2017). doi:10.1371/journal.pone.0186459 ↩
Navas, L.E. & Carnero, A., “NAD+ metabolism, stemness, the immune response, and cancer,” Signal Transduction and Targeted Therapy 6, 2 (2021). doi:10.1038/s41392-020-00354-w ↩